10X Genomics Inc (NASDAQ:TXG) — Market Cap & Net Worth
Market Cap & Net Worth: 10X Genomics Inc (TXG)
10X Genomics Inc (NASDAQ:TXG) has a market capitalization of $8.77 Billion ($8.77 Billion) as of September 16, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #2473 globally and #908 in its home market, demonstrating a 18.74% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying 10X Genomics Inc's stock price $74.39 by its total outstanding shares 120212296 (120.21 Million). Also see total assets of 10X Genomics Inc for a full breakdown of the balance sheet.
10X Genomics Inc Market Cap History: 2019 to 2026
10X Genomics Inc's market capitalization history from 2019 to 2026. Data shows growth from $9.17 Billion to $8.94 Billion (5.02% CAGR). Also see TXG operating cash flow for how efficiently the company converts equity into cash flow.
Index Memberships
10X Genomics Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.66 Trillion | 0.33% | #56 of 976 |
|
NASDAQ Composite
IXIC
|
$41.74 Trillion | 0.02% | #287 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.88 Trillion | 0.47% | #38 of 263 |
Weight: 10X Genomics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
10X Genomics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how 10X Genomics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check TXG share price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
3.05x
10X Genomics Inc's market cap is 3.05 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2019 | $9.17 Billion | $245.89 Million | -$31.25 Million | 37.28x | N/A |
| 2020 | $17.02 Billion | $298.85 Million | -$542.73 Million | 56.96x | N/A |
| 2021 | $17.91 Billion | $490.49 Million | -$58.22 Million | 36.51x | N/A |
| 2022 | $4.38 Billion | $516.41 Million | -$166.00 Million | 8.48x | N/A |
| 2023 | $6.73 Billion | $618.73 Million | -$255.10 Million | 10.87x | N/A |
| 2024 | $1.73 Billion | $610.78 Million | -$182.63 Million | 2.83x | N/A |
| 2025 | $1.96 Billion | $642.82 Million | -$43.54 Million | 3.05x | N/A |
Competitor Companies of TXG by Market Capitalization
Companies near 10X Genomics Inc in the global market cap rankings as of September 16, 2026. Review 10X Genomics Inc tangible net worth ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to 10X Genomics Inc by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #125 globally with a market cap of $177.42 Billion USD.
- Medtronic PLC (NYSE:MDT): Ranked #229 globally with a market cap of $109.30 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #232 globally with a market cap of $107.98 Billion USD.
- Medtronic plc (SA:MDTC34): Ranked #239 globally with a market cap of $104.84 Billion USD ( R$534.32 Billion BRL).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #125 | Abbott Laboratories | NYSE:ABT | $177.42 Billion | $102.03 |
| #229 | Medtronic PLC | NYSE:MDT | $109.30 Billion | $93.75 |
| #232 | Stryker Corporation | NYSE:SYK | $107.98 Billion | $281.50 |
| #239 | Medtronic plc | SA:MDTC34 | $104.84 Billion | R$208.39 |
10X Genomics Inc Historical Marketcap From 2019 to 2026
Between 2019 and today, 10X Genomics Inc's market cap moved from $9.17 Billion to $ 8.94 Billion, with a yearly change of 5.02%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $8.94 Billion | +356.10% |
| 2025 | $1.96 Billion | +13.58% |
| 2024 | $1.73 Billion | -74.34% |
| 2023 | $6.73 Billion | +53.57% |
| 2022 | $4.38 Billion | -75.54% |
| 2021 | $17.91 Billion | +5.20% |
| 2020 | $17.02 Billion | +85.70% |
| 2019 | $9.17 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 16th, 2026 the market cap of 10X Genomics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $8.77 Billion USD |
| MoneyControl | $8.77 Billion USD |
| MarketWatch | $8.77 Billion USD |
| marketcap.company | $8.77 Billion USD |
| Reuters | $8.77 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About 10X Genomics Inc
10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. The company offers Chromium platform, a single cell portfolio that enables analysis of individual biological components, as well as includes microfluidic chips and related… Read more